Abstract:Objective: To investigate the mutation of the KRAS/NRAS/BRAF/PIK3CA gene and its relationship with clinicopathological features in colorectal cancer (CRC). Methods: The surgical resection specimens of 91 patients with primary CRC from 2012 to 2016 in Shanghai Fifth People's Hospital affiliated with Fudan University were collected for retrospective analysis. Detecting mutations in the KRAS/NRAS/BRAF/PIK3CA genes were confirmed by an amplification-refractory mutation system (ARMS). Immunohistochemistry (IHC) was conducted to confirm the expression of KRAS, NRAS, BRAF, and PIK3CA proteins.Results: Among 91 CRC patients, the mutation rates of the KRAS, NRAS, BRAF, and PIK3CA genes were 40.7% (37/91), 4.4% (4/91), 3.3% (3/91) and 2.2% (2/91), respectively. The KRAS/PIK3CA double mutation rate was 2.2% (2/91), and the KRAS/NRAS double mutation rate was 1.1% (1/91). The mutation rate of the BRAF gene in poorly differentiated CRC patients was significantly higher than that in moderately to well-differentiated patients (P < 0.05). PIK3CA gene mutation was significantly different between primary tumour sites (P < 0.05). The mutation rate of the KRNS/NRAS/BRAF/PIK3CA genes in patients with lymph node metastasis (78.3%, 18/23) was significantly higher than that in patients without lymph node metastasis (45.6%, 31/68) (P < 0.05). No significant differences in immunohistochemical expression between KRAS-, NRAS-, BRAF-, and PIK3CA-mutant patients and nonmutated patients were confirmed (P>0.05). Conclusions: KRAS mutation is the most common mutated gene in CRC patients. PIK3CA mutation is often accompanied by KRAS mutation, and EGFR treatment resistance in KRAS wild-type patients may be caused by PIK3CA gene mutation. Simultaneous detection of KRAS/NRAS/BRAF/PIK3CA gene mutations helps to develop the most accurate treatment for CRC patients. KRAS/NRAS/BRAF/PIK3CA gene mutations were associated with several clinicopathological features in this group of CRC patients, but more cases need to be confirmed by further studies. Gene mutations in CRC patients are best detected by DNA sequencing or ARMS methods.Funding Information: This work was supported by the High-level Professional Physician Training Program of Minhang District, Shanghai City (No. 2020MZYS10).Declaration of Interests: None.Ethics Approval Statement: The study was approved by the Ethical Committee of Shanghai Fifth People's Hospital, Fudan University (No. 2021071). Patients did not need to give informed consent because anonymous data were used in the analysis, which were obtained after each patient's written consent to treatment.

Epidemiological and clinicopathological features of KRAS, NRAS, BRAF mutations and MSI in Chinese patients with stage I–III colorectal cancer

KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer.

Comprehensive analysis of gene mutations and mismatch repair in Chinese colorectal cancer patients

[KRAS and BRAF Gene Mutations in Correlation with Clinicopathologic Features of Colorectal Carcinoma in Chinese].

A Study of Gene Variation in All-RAS Wild-Type Metastatic Colorectal Cancer and Its Correlation with Cetuximab.

Mutations of KRAS and BRAF in Chinese Patients with Colorectal Carcinoma : Analyses of 966 Cases

Correlation Between Clinicopathological Features and KRAS, NRAS, and BRAF Mutation Status in Chinese Colorectal Cancer Patients

KRAS, NRAS, BRAF Signatures, and MMR Status in Colorectal Cancer Patients in North China

Clinicopathologic Features and Prognostic Value of KRAS, NRAS and BRAF Mutations and DNA Mismatch Repair Status: A Single‐center Retrospective Study of 1,834 Chinese Patients with Stage I–IV Colorectal Cancer

A Study on the Relationship Between KRAS, NRAS, BRAF and PIK3CA Gene Mutations and Clinicopathological Features in Patients with Colorectal Cancer

KRAS and BRAF Gene Mutations and DNA Mismatch Repair Status in Chinese Colorectal Carcinoma Patients.

Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients.

Molecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutations

Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients

Detection of KRAS mutations and their associations with clinicopathological features and survival in Chinese colorectal cancer patients.

Mutations in KRAS Codon 12 Predict Poor Survival in Chinese Patients with Metastatic Colorectal Cancer.

Clinic-pathological characteristics of MMR protein, KRAS-NRAS-BRAF gene mutation, HER-2 and PD-L1 status in 3822 Chinese colorectal cancer patients

Clinical-Molecular Characteristics and Post-Translational Modifications of Colorectal Cancer in North China: Implications for Future Targeted Therapies

Genomic Alterations and Clinical Characterization in Chinese Patients with Metastatic Colorectal Cancer

Demographic trends and KRAS/BRAFV600E mutations in colorectal cancer patients of South China: A single-site report

Mutations in Epidermal Growth Factor Receptor and K-ras in Chinese Patients with Colorectal Cancer